Literature DB >> 22022816

Delayed mortality in a cohort of persons hospitalized with West Nile virus disease in Colorado in 2003.

Nicole P Lindsey1, James J Sejvar, Amy V Bode, W John Pape, Grant L Campbell.   

Abstract

Most mortality associated with West Nile virus (WNV) disease occurs during the acute or early convalescent phases of illness. However, some reports suggest mortality may be elevated for months or longer after acute illness. The objective of this study was to assess the survival of a cohort of patients hospitalized with WNV disease in Colorado in 2003 up to 4 years after illness onset. We calculated age-adjusted standardized mortality ratios (SMRs) to evaluate excess mortality, evaluated reported causes of death in those who died, and analyzed potential covariates of delayed mortality. By 1 year after illness onset, 4% of the 201 patients had died (SMR, 2.7; 95% confidence interval [CI], 1.3-5.2), and 12% had died by 4 years after onset (SMR, 2.0; 95% CI, 1.3-3.0). Among those who had died, the most common immediate and contributory causes of death included pulmonary disease and cardiovascular disease; cancer, hepatic disease, and renal disease were mentioned less frequently. In multivariate analysis, age (hazard ratio [HR], 2.0 per 10-year increase; 95% CI, 1.4-2.7), autoimmune disease (HR, 3.0; 95% CI, 1.1-7.9), ever-use of tobacco (HR, 3.0; 95% CI, 1.3-7.0), encephalitis during acute WNV illness (HR, 2.6; 95% CI, 1.1-6.4), and endotracheal intubation during acute illness (HR 4.8; 95% CI, 1.9-12.1) were found to be independently associated with mortality. Our finding of an approximate twofold increase in mortality for up to 3 years after acute illness reinforces the need for prevention measures against WNV infection among at-risk groups to reduce acute as well as longer-term adverse outcomes.

Entities:  

Mesh:

Year:  2011        PMID: 22022816     DOI: 10.1089/vbz.2011.0721

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  16 in total

Review 1.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

2.  Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines.

Authors:  Melissa N Garcia; Anne M Hause; Christopher M Walker; Jordan S Orange; Rodrigo Hasbun; Kristy O Murray
Journal:  Viral Immunol       Date:  2014-07-25       Impact factor: 2.257

Review 3.  West Nile Virus: biology, transmission, and human infection.

Authors:  Tonya M Colpitts; Michael J Conway; Ruth R Montgomery; Erol Fikrig
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 4.  West Nile virus: review of the literature.

Authors:  Lyle R Petersen; Aaron C Brault; Roger S Nasci
Journal:  JAMA       Date:  2013-07-17       Impact factor: 56.272

5.  Clinical Spectrum of West Nile Virus Neuroinvasive Disease.

Authors:  Andrew Yu; Emily Ferenczi; Kareem Moussa; Dean Eliott; Marcelo Matiello
Journal:  Neurohospitalist       Date:  2019-08-13

6.  Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.

Authors:  Juliette K Tinker; Jie Yan; Reece J Knippel; Panos Panayiotou; Kenneth A Cornell
Journal:  Toxins (Basel)       Date:  2014-04-22       Impact factor: 4.546

7.  Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort.

Authors:  Melissa S Nolan; Amber S Podoll; Anne M Hause; Katherine M Akers; Kevin W Finkel; Kristy O Murray
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

8.  West Nile virus infection among humans, Texas, USA, 2002-2011.

Authors:  Melissa S Nolan; Jim Schuermann; Kristy O Murray
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

9.  West Nile virus, Texas, USA, 2012.

Authors:  Kristy O Murray; Duke Ruktanonchai; Dawn Hesalroad; Eric Fonken; Melissa S Nolan
Journal:  Emerg Infect Dis       Date:  2013-11       Impact factor: 6.883

10.  Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort.

Authors:  Kristy O Murray; Melissa N Garcia; Mohammad H Rahbar; Diana Martinez; Salma A Khuwaja; Raouf R Arafat; Susan Rossmann
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.